Expesicor Receives Fast-Track SBIR Grant From The National Institutes Of Health

Expescor获美国国立卫生研究院快速SBIR资助,用于神经障碍治疗

2019-10-09 17:47:21 BioSpace

本文共876个字,阅读需3分钟

Expesicor, a privately held, Montana-based company focused on preventing, treating, and curing neurological disorders, today announced that the National Institute of Neurological Disorders and Stroke , part of the National Institutes of Health , has awarded the company $343,042 over one year for the first phase of a Small Business Innovation Research grant award. The three-year fast-track award is for Expesicor to further develop its proprietary KaL model™ of neurodegeneration and epilepsy. The total grant has the potential to provide a total of $1.4 million in nondilutive financial resources. "We're very excited about this funding and greatly appreciate the NIH's support," said Braxton Norwood, PhD Principal Investigator and CEO of Expesicor. "This award enables us to substantially accelerate and expand development of our patent-pending KaL model™, which we and our collaborators have found to be an invaluable drug discovery tool." Expesicor is a clinical-stage company with a development pipeline ranging from preclinical to Phase II clinical trials. The company's assets include therapeutics and drug screening tools targeting epilepsy, neurodegenerative disorders, and other central nervous system disorders/injuries. Research reported in this publication was supported by the National Institute of Neurological Disorders and Stroke of the National Institutes of Health under Award Number R44NS112039. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health. About Expesicor Expesicor is a clinical stage, privately-held, Montana-based company focused on preventing, treating, and curing neurological disorders. For more information, visit expesicor.com. Forward-Looking Statement This news release of Expesicor Inc., Kalispell, MT, USA (the "company") includes "forward-looking statements" within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. These statements are based upon the current beliefs and expectations of the company's management and are subject to significant risks and uncertainties. There can be no guarantees with respect to pipeline products that the products will receive the necessary regulatory approvals or that they will prove to be commercially successful. If underlying assumptions prove inaccurate, or risks or uncertainties materialize, actual results may differ materially from those set forth in the forward-looking statements. Risks and uncertainties include, but are not limited to, general industry conditions and competition; general economic factors; the impact of pharmaceutical industry regulation and health care legislation in the United States and internationally; technological advances; challenges inherent in new product development, including obtaining regulatory approval; and the exposure to litigation. The company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events, or otherwise. Contact: Expesicor Inc. PO Box 10205 350 N Meridian Rd Kalispell, MT 59901 Press: press@expesicor.com View original content:http://www.prnewswire.com/news-releases/expesicor-receives-fast-track-sbir-grant-from-the-national-institutes-of-health-300931534.html SOURCE Expesicor
位于蒙大拿州的一家私人控股公司 Expeescor ,致力于预防、治疗和治疗神经障碍,今天宣布国家神经疾病和中风研究所,国家卫生研究院的一部分,已为小企业创新研究基金的第一阶段拨款超过一年的343,042元。为期三年的快速奖项是为 Expeescor 进一步开发其专有的 KaL 模型™神经变性和癫痫。赠款总额有可能提供总额140万美元的非稀释财政资源。 Expeescor 首席研究员兼首席执行官 Braxton Norwood 博士说:“我们对这笔资金非常兴奋,非常感谢 NIH 的支持。”“这个奖项使我们能够大大加快和扩大我们正在申请专利的 KaL 模型™的开发,我们和我们的合作者发现这是一个宝贵的药物发现工具。” Expesicol 是一家临床阶段公司,拥有从临床前到 II 期临床试验的开发管线。公司资产包括针对癫痫、神经退行性疾病以及其他中枢神经系统疾病/损伤的治疗药物和药物筛选工具。 本出版物中所报道的研究得到了美国国立卫生研究院神经疾病和中风研究所的支持,编号为 R4NS112039。内容完全是作者的责任,不一定代表国家卫生研究院的官方观点。 关于 Expeescor Expeescor 是一家临床阶段的私人控股的蒙大拿州公司,专注于预防、治疗和治疗神经障碍。更多信息,请访问体验者。com 。 前瞻性陈述 本新闻稿的 Expescor 公司,卡尔斯皮尔, MT ,美国(“公司”)包括“前瞻性声明”的含义,安全港规定的美国私人证券诉讼改革法案1995年。本声明是基于公司管理层目前的信念和预期,存在重大风险和不确定性。对于管道产品,无法保证产品将获得必要的监管批准,或证明产品在商业上取得成功。如果基本假设被证明不准确,或风险或不确定性出现,实际结果可能与前瞻性陈述中的结果存在重大差异。风险和不确定性包括但不限于一般行业条件和竞争;一般经济因素;美国和国际医药行业监管和卫生保健立法的影响;技术进步;新产品开发固有的挑战,包括获得监管批准;以及诉讼风险。公司不承担因新信息、未来事项或其他原因而公开更新任何前瞻性声明的义务。

以上中文文本为机器翻译,存在不同程度偏差和错误;偶尔因源网页结构局限,内容无法一次完整呈现。请理解并参考原站原文阅读。

阅读原文